Need professional-grade analysis? Visit stockanalysis.com
$14.57B
N/A
N/A
N/A
Vigonvita Life Sciences Co Ltd (2630) trades on Hong Kong Stock Exchange in HKD. The company is classified in the Healthcare sector under the Drug Manufacturers - General industry. The stock currently trades at HKD85.25, down 2.01% from the previous close.
Over the past year, 2630 has traded between a low of HKD52.85 and a high of HKD131.00. The stock has gained 4.0% over this period. It is currently 34.9% below its 52-week high.
Vigonvita Life Sciences Co Ltd has a market capitalization of $14.57B.
Vigonvita Life Sciences Co., Ltd., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for neuropsychiatry, reproductive health, and viral infection therapeutic areas. Its lead products include LV232, a first-in-class dual-target serotonin transporter/5-hydroxytryptamine 3 receptor modulators, which is in Phase II of clinical trial for the treatment of depressive disorder; and TPN171, a type-5 phosphodiesterase inhibitor completed Phase III clinical trial for the treatment of erectile dysfunction. The company also develops VV116, a RdRp inhibitor completed a Phase II clinical trial for the treatment of respiratory syncytial virus infection; TPN102, a voltage-gated sodium and calcium channels inhibitor, which is in Phase I clinical trial for the treatment epilepsy; VV119, a multi-target serotonin-dopamine activity modulator, which is in Phase I clinical trial for the treatment of psychiatric disorders and schizophrenia; VV261, an antiviral nucleoside prodrug, which is in Phase I clinical trial for RNA viruses, including coronavirus, influenza virus, arenavirus, and RSV. In addition, its preclinical products include VV147, a small molecule drug candidate that regulates the glutamatergic system for the treatment of depression; VV913, a small molecule with a novel structure designed for regulating the monoaminergic system to treat premature ejaculation; and VV207, an orally administered nucleoside prodrug with a novel structure, exhibiting broad-spectrum antiviral activity against DNA viruses. The company was incorporated in 2013 and is headquartered in Suzhou, China.
Side-by-side comparison against top Healthcare peers.